PDF(Pubmed)
Abstract：
UNASSIGNED: Ocular vascular diseases are common causes of visual impairment and blindness, for which anti-vascular endothelial growth factor (anti-VEGF) is the first-line therapy. Current study describes the profile of patients receiving intravitreal anti-VEGF injections (IVI), and gender variation in Bhutan. The study was designed to inform national health policy.
UNASSIGNED: Retrospective cross-sectional study.
UNASSIGNED: We reviewed the surgical registers of the vitreoretinal (VR) units across Bhutan over three years. Patient demography, clinical findings, diagnostic tests performed, and diagnoses or indications for IVI were logged. A descriptive analysis was performed.
UNASSIGNED: Despite limited availability of anti-VEGF, a total of 381 patients received IVI in operating theatres as mandated by the national guidelines. The majority of patients were males (230, 60.4%, p = 0.004). The mean age was 65.2 ± 13.5 years (range 13 years to 90 years), and a median of 69 years. The majority of the treated eyes (117, 30.7%) had BCVA <3/60 to light perception (PL), and another 51 eyes (13.4%) had < 6/60 to 3/60. The most common indication for IVI was neovascular age-related macular degeneration (nAMD) (168 cases, 42.2%), followed by retinal vein occlusion (RVO) (132 cases, 34.6%), diabetic macular oedema (DMO) and retinopathy (DR) (50 cases, 13.1%), and myopic choroidal neovascular membrane (11 cases, 0.03%).
UNASSIGNED: Limited human resources for managing VR diseases in Bhutan are compounded by economic and geographic challenges. With increasing VR diseases such as nAMD and myopia and complications of systemic diseases such as DR, DMO and RVO, there is a need to improve VR services. Currently, anti-VEGF is procured only for a pooled patients requiring IVI, and patients are lost due to longer waiting periods. Bhutan needs to assess if females are reporting less or are not receiving treatment due to cultural barriers and social stigma.
UNASSIGNED: Retrospective cross-sectional study.
UNASSIGNED: We reviewed the surgical registers of the vitreoretinal (VR) units across Bhutan over three years. Patient demography, clinical findings, diagnostic tests performed, and diagnoses or indications for IVI were logged. A descriptive analysis was performed.
UNASSIGNED: Despite limited availability of anti-VEGF, a total of 381 patients received IVI in operating theatres as mandated by the national guidelines. The majority of patients were males (230, 60.4%, p = 0.004). The mean age was 65.2 ± 13.5 years (range 13 years to 90 years), and a median of 69 years. The majority of the treated eyes (117, 30.7%) had BCVA <3/60 to light perception (PL), and another 51 eyes (13.4%) had < 6/60 to 3/60. The most common indication for IVI was neovascular age-related macular degeneration (nAMD) (168 cases, 42.2%), followed by retinal vein occlusion (RVO) (132 cases, 34.6%), diabetic macular oedema (DMO) and retinopathy (DR) (50 cases, 13.1%), and myopic choroidal neovascular membrane (11 cases, 0.03%).
UNASSIGNED: Limited human resources for managing VR diseases in Bhutan are compounded by economic and geographic challenges. With increasing VR diseases such as nAMD and myopia and complications of systemic diseases such as DR, DMO and RVO, there is a need to improve VR services. Currently, anti-VEGF is procured only for a pooled patients requiring IVI, and patients are lost due to longer waiting periods. Bhutan needs to assess if females are reporting less or are not receiving treatment due to cultural barriers and social stigma.
摘要：
眼部血管疾病是视力障碍和失明的常见原因，抗血管内皮生长因子（抗VEGF）是一线治疗。目前的研究描述了接受玻璃体内注射抗VEGF（IVI）的患者的概况，不丹的性别差异。该研究旨在为国家卫生政策提供信息。
■回顾性横断面研究。
■我们回顾了三年来不丹玻璃体视网膜（VR）单位的手术记录。患者人口统计学,临床发现，进行的诊断测试，并记录IVI的诊断或适应症。进行了描述性分析。
■尽管抗VEGF的应用有限，根据国家指南的规定,共有381例患者在手术室接受了IVI.大多数患者是男性（230，60.4%，p=0.004)。平均年龄为65.2±13.5岁（13岁至90岁），中位数为69岁。大多数治疗的眼睛（117，30.7％）的BCVA<3/60的光感知（PL），另外51只眼(13.4%)<6/60至3/60。IVI最常见的指征是新生血管性年龄相关性黄斑变性（nAMD）（168例，42.2%)，其次是视网膜静脉阻塞（RVO）（132例，34.6%），糖尿病性黄斑水肿（DMO）和视网膜病变（DR）（50例，13.1%），和近视脉络膜新生血管膜（11例，0.03%）。
■不丹管理VR疾病的人力资源有限，加上经济和地理挑战。随着nAMD、近视等VR疾病和DR等全身性疾病并发症的增多,DMO和RVO,需要改进VR服务。目前,抗VEGF仅适用于需要IVI的合并患者，和病人失去了由于较长的等待时间。不丹需要评估女性是否因文化障碍和社会耻辱而报告较少或没有接受治疗。
■回顾性横断面研究。
■我们回顾了三年来不丹玻璃体视网膜（VR）单位的手术记录。患者人口统计学,临床发现，进行的诊断测试，并记录IVI的诊断或适应症。进行了描述性分析。
■尽管抗VEGF的应用有限，根据国家指南的规定,共有381例患者在手术室接受了IVI.大多数患者是男性（230，60.4%，p=0.004)。平均年龄为65.2±13.5岁（13岁至90岁），中位数为69岁。大多数治疗的眼睛（117，30.7％）的BCVA<3/60的光感知（PL），另外51只眼(13.4%)<6/60至3/60。IVI最常见的指征是新生血管性年龄相关性黄斑变性（nAMD）（168例，42.2%)，其次是视网膜静脉阻塞（RVO）（132例，34.6%），糖尿病性黄斑水肿（DMO）和视网膜病变（DR）（50例，13.1%），和近视脉络膜新生血管膜（11例，0.03%）。
■不丹管理VR疾病的人力资源有限，加上经济和地理挑战。随着nAMD、近视等VR疾病和DR等全身性疾病并发症的增多,DMO和RVO,需要改进VR服务。目前,抗VEGF仅适用于需要IVI的合并患者，和病人失去了由于较长的等待时间。不丹需要评估女性是否因文化障碍和社会耻辱而报告较少或没有接受治疗。
